Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

BACKGROUND: The effectiveness of ustekinumab (UST) in the treatment of Crohn’s disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naïve and anti-TNF-exposed patients. Given the selective nature of pivotal trial designs, real-world effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Parra, Rogério Serafim, Chebli, Júlio Maria Fonseca, Queiroz, Natália Sousa Freitas, Damião, Aderson Omar Mourão Cintra, de Azevedo, Matheus Freitas Cardoso, Chebli, Liliana Andrade, Bertges, Erika Ruback, Alves Junior, Antonio José Tiburcio, Ambrogini Junior, Orlando, da Silva, Bianca Loyo Pona Schiavetti, Lubini, Marcio, Bafutto, Mauro, Flores, Cristina, Vilela, Eduardo Garcia, Boratto, Sandra Felice, Gasparetti Junior, Newton Luiz Tricarico, Steinwurz, Flavio, Carvalho, Nayara Salgado, Féres, Omar, da Rocha, José Joaquim Ribeiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027080/
https://www.ncbi.nlm.nih.gov/pubmed/35448949
http://dx.doi.org/10.1186/s12876-022-02280-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027080/
https://www.ncbi.nlm.nih.gov/pubmed/35448949
http://dx.doi.org/10.1186/s12876-022-02280-3

Ejemplares similares